Actuate Therapeutics is a clinical-stage pharmaceutical company focused on developing and commercializing novel therapeutic agents for cancer and inflammatory diseases. Its lead program centers on 9-ING-41, which is being evaluated in the 1801 histology-agnostic clinical trial designed to move from single-agent testing to six different combinations with standard-of-care chemotherapies. The company plans to expand the 1801 trial to include an arm combining 9-ING-41 with irinotecan. With the additional $6.5M Series B-3 financing (bringing total Series B funding to over $28.2M), Actuate intends to initiate a Phase 2 clinical trial in myelofibrosis. Leadership includes President & CEO Daniel Schmitt, CMO Dr. Frank Giles, and Lead, Medical Affairs Dr. Ludimila Cavalcante. Initial combination regimens were prioritized based on preclinical evidence showing reversal of resistance to key cytotoxic agents in diverse models. Actuate Therapeutics is a Fort Worth, TX-based clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutic agents for cancer and inflammatory diseases. Its lead program is 9-ING-41, a glycogen synthase kinase-3 beta (GSK-3β) inhibitor being evaluated as a single agent and in combination with chemotherapy. The company is quickly advancing the 1801 Phase 1/2 clinical trial in adult cancer patients in the U.S. and has treated the first patient at Brown University/Rhode Island Hospital. The financing will support expansion of the 1801 trial into its U.S. and European oncology research network, initiation of investigator-initiated trials with physician/scientist collaborators, and advancement of a pediatric neuroblastoma program. Actuate is led by President & CEO Daniel Schmitt and Chief Medical Officer Dr. Frank Giles. The company raised capital in a Series B to fund these development activities.

Total raised

$28M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2019